on Heidelberg Pharma AG (ETR:HPHA)
Heidelberg Pharma Announces Executive Board Change
Heidelberg Pharma AG, a clinical-stage biotech company, has announced an upcoming change in its executive board. Walter Miller, the current Chief Financial Officer (CFO), will step down at the end of April 2026. The Supervisory Board has appointed Peter Willinger as the new CFO, effective May 1, 2026. This transition occurs as the company advances its Phase I/IIa trial with its lead ADC candidate, HDP-101.
Peter Willinger brings over 20 years of CFO experience from notable biotech firms. His expertise includes IPOs, M&A activities, and managing finance-related departments. CEO Dr. Dongzhou Jeffery Liu and Chairman Karl Benedikt Biesinger expressed gratitude for Miller's service and confidence in Willinger's leadership.
Heidelberg Pharma's work on Amanitin-based ADC technology continues, focusing on multiple clinical developments. Willinger looks forward to driving the company's sustainable growth in this pivotal phase.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Heidelberg Pharma AG news